Incidence OIRD Medical and Trauma Patients

July 29, 2019 updated by: Susan Dempsey Ortega, Fresno Community Hospital and Medical Center

Incidence of OIRD in Medical and Trauma Patients on the General Care Floor Receiving PCA or Nurse Administered Intravenous Opioids Monitored by Capnography and Pulse Oximetry: A Prospective, Blinded Observational Study

The primary objective of this prospective, blinded observational study is to correlate assessment of sedation and respiratory status with capnography and pulse oximetry monitoring in hospitalized adult medical and trauma patients receiving patient-controlled analgesia (PCA) or nurse administered intravenous opioids for acute pain. Nursing assessment of respiratory status and sedation level will be correlated with capnography and pulse oximetry values as technology-supported monitoring to identify respiratory depression and opioid-induced sedation. The secondary objective is to identify capnography and pulse oximetry values that correlate with respiratory decompensation and opioid-induced sedation in medical and trauma patients on the general care floor.

Study Overview

Status

Unknown

Study Type

Observational

Enrollment (Anticipated)

101

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Fresno, California, United States, 93621
        • Community Regional Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 89 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The target study population will be hospitalized, adult medical or trauma patients on the general care floor receiving patient-controlled analgesia or nurse administered intravenous opioids for acute pain.

Description

Inclusion Criteria:

  1. Spontaneously breathing adults 18 to 89 years of age
  2. Receiving PCA or nurse administered IV opioids for medical or trauma-related pain
  3. Admitted to the general care floor from the emergency department
  4. Able to provide written informed consent

Exclusion Criteria:

  1. Age is less than 18 years or greater than 89 years
  2. Transfer to the general care floor from the ICU
  3. Provider order for respiratory monitoring using continuous capnography
  4. Receiving intrathecal or epidural opioids
  5. Trauma patient with a nerve block
  6. Inability or unwillingness to wear the EtCO2 sampling line nasal cannula or pulse oximetry sensor
  7. History or diagnosis of a sleep disordered breathing syndrome
  8. Use of CPAP or BIPAP non-invasive ventilation as home regime
  9. Pre-existing co-morbidity that impacts respiration or ventilation (e.g. COPD or pulmonary fibrosis) (for the purpose of this study a trauma patient with rib fractures is not considered having a pre-existing condition)
  10. Receiving non-invasive ventilation
  11. Unable or unwilling to participate
  12. Member of a vulnerable population such as pregnant women or prisoners

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hypoventilation
Time Frame: Change from baseline measurement observed within 60 minutes after opioid administration
The number of subjects who experience hypoventilation using respiratory monitoring with continuous capnography for data collection.
Change from baseline measurement observed within 60 minutes after opioid administration
Hypoventilation
Time Frame: Change from baseline measurement observed within 60 minutes after opioid administration
The percentage of subjects who experience hypoventilation using respiratory monitoring with continuous capnography for data collection.
Change from baseline measurement observed within 60 minutes after opioid administration
Hypoventilation
Time Frame: Change from baseline measurement observed within 60 minutes after opioid administration
The characteristics of subjects who experience hypoventilation using respiratory monitoring with continuous capnography for data collection.
Change from baseline measurement observed within 60 minutes after opioid administration

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hypoxemia
Time Frame: Change from baseline measurement observed within 60 minutes after opioid administration ]
The number of subjects who experience oxygen desaturation using respiratory monitoring with continuous pulse oximetry for data collection.
Change from baseline measurement observed within 60 minutes after opioid administration ]
Hypoxemia
Time Frame: Change from baseline measurement observed within 60 minutes after opioid administration ]
The percentage of subjects who experience oxygen desaturation using respiratory monitoring with continuous pulse oximetry for data collection.
Change from baseline measurement observed within 60 minutes after opioid administration ]
Hypoxemia
Time Frame: Change from baseline measurement observed within 60 minutes after opioid administration ]
The characteristics of subjects who experience oxygen desaturation using respiratory monitoring with continuous pulse oximetry for data collection.
Change from baseline measurement observed within 60 minutes after opioid administration ]

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sedation
Time Frame: Change from baseline assessment observed within 60 minutes after opioid administration ]
The number of subjects who experience unintended sedation using the Pasero Opioid-Induced Sedation Scale in which sedation levels of S, 1, 2, 3, 4 are assessed where "S" represents normal sleep, increasing numbers represent increasing levels of sedation, and sedation levels 3 or 4 indicate unintended opioid-induced sedation for the purpose of this study
Change from baseline assessment observed within 60 minutes after opioid administration ]
Sedation
Time Frame: Change from baseline assessment observed within 60 minutes after opioid administration ]
The percentage of subjects who experience unintended sedation using the Pasero Opioid-Induced Sedation Scale in which sedation levels of S, 1, 2, 3, 4 are assessed where "S" represents normal sleep, increasing numbers represent increasing levels of sedation, and sedation levels 3 or 4 indicate unintended opioid-induced sedation for the purpose of this study
Change from baseline assessment observed within 60 minutes after opioid administration ]
Sedation
Time Frame: Change from baseline assessment observed within 60 minutes after opioid administration ]
The characteristics of subjects who experience unintended sedation using the Pasero Opioid-Induced Sedation Scale in which sedation levels of S, 1, 2, 3, 4 are assessed where "S" represents normal sleep, increasing numbers represent increasing levels of sedation, and sedation levels 3 or 4 indicate unintended opioid-induced sedation for the purpose of this study
Change from baseline assessment observed within 60 minutes after opioid administration ]
Sedation
Time Frame: Change from baseline assessment observed within 60 minutes after opioid administration
The number of subjects who experience unintended sedation using the Moline Roberts Pharmacologic Sedation Scale in which sedation levels of 1, 2, 3, 4, 5, 6 are assessed where increasing numbers represent increasing levels of sedation and sedation levels 3 or 4 or 5 or 6 indicate unintended opioid-induced sedation for the purpose of this study
Change from baseline assessment observed within 60 minutes after opioid administration
Sedation
Time Frame: Change from baseline assessment observed within 60 minutes after opioid administration
The percentage of subjects who experience unintended sedation using the Moline Roberts Pharmacologic Sedation Scale in which sedation levels of 1, 2, 3, 4, 5, 6 are assessed where increasing numbers represent increasing levels of sedation and sedation levels 3 or 4 or 5 or 6 indicate unintended opioid-induced sedation for the purpose of this study
Change from baseline assessment observed within 60 minutes after opioid administration
Sedation
Time Frame: Change from baseline assessment observed within 60 minutes after opioid administration
The characteristics of subjects who experience unintended sedation using the Moline Roberts Pharmacologic Sedation Scale in which sedation levels of 1, 2, 3, 4, 5, 6 are assessed where increasing numbers represent increasing levels of sedation and sedation levels 3 or 4 or 5 or 6 indicate unintended opioid-induced sedation for the purpose of this study
Change from baseline assessment observed within 60 minutes after opioid administration
Sedation
Time Frame: Change from baseline assessment observed within 60 minutes after opioid administration
The number of subjects who experience unintended sedation using the Richmond Agitation Sedation Scale in which sedation levels of +4, +3, +2, +1, 0, -1, -2, -3, -4, -6 are assessed where decreasing numbers represent increasing levels of sedation and sedation levels of -1 or -2 or -3 or -4 or -5 indicate unintended opioid-induced sedation for the purpose of this study
Change from baseline assessment observed within 60 minutes after opioid administration
Sedation
Time Frame: Change from baseline assessment observed within 60 minutes after opioid administration
The percentage of subjects who experience unintended sedation using the Richmond Agitation Sedation Scale in which sedation levels of +4, +3, +2, +1, 0, -1, -2, -3, -4, -6 are assessed where decreasing numbers represent increasing levels of sedation and sedation levels of -1 or -2 or -3 or -4 or -5 indicate unintended opioid-induced sedation for the purpose of this study
Change from baseline assessment observed within 60 minutes after opioid administration
Sedation
Time Frame: Change from baseline assessment observed within 60 minutes after opioid administration
The characteristics of subjects who experience unintended sedation using the Richmond Agitation Sedation Scale in which sedation levels of +4, +3, +2, +1, 0, -1, -2, -3, -4, -6 are assessed where decreasing numbers represent increasing levels of sedation and sedation levels of -1 or -2 or -3 or -4 or -5 indicate unintended opioid-induced sedation for the purpose of this study
Change from baseline assessment observed within 60 minutes after opioid administration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Susan J Dempsey, PhD(c), UCLA and Community Regional Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 29, 2019

Primary Completion (ANTICIPATED)

October 29, 2019

Study Completion (ANTICIPATED)

November 29, 2019

Study Registration Dates

First Submitted

May 10, 2019

First Submitted That Met QC Criteria

May 10, 2019

First Posted (ACTUAL)

May 14, 2019

Study Record Updates

Last Update Posted (ACTUAL)

July 31, 2019

Last Update Submitted That Met QC Criteria

July 29, 2019

Last Verified

July 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • FresnoCHMC

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sedation

3
Subscribe